Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, ...

The latest update is out from Traws Pharma ( (TRAW) ).

WHEN YOU HAVE COVID and aren’t feeling well, you may worry about your symptoms getting worse and that you might end up in the hospital. One option that you have to potentially keep that from happening ...

President Joe Biden announced he has COVID on Wednesday. The White House says his symptoms are mild, including a runny nose, cough, and malaise. He's taking the antiviral Paxlovid, but recent studies ...

The Food and Drug Administration has set March 8 as the end of its emergency use authorization (EUA) for Paxlovid for adult patients, the agency has said this week. The medication is given to those ...

Most of us are pretty adept by now at managing COVID-19, with an armor of past infections, vaccinations, self-tests, and antiviral medications like Paxlovid. In the latest study, however, researchers ...

SAN FRANCISCO -- The popular COVID treatment, Paxlovid, does not significantly lower the risk of "long COVID" for people who are vaccinated. In a new study from UCSF, researchers found that patients ...

COVID-19 has become less of an urgent threat than it was in 2019 largely because of vaccines and growing immunity from natural infections, but antiviral treatments have also changed the course of the ...

Traws Pharma (TRAW) announced the dosing of the first subject in a Phase 2 study to evaluate ratutrelvir, a ritonavir-free anti-viral treatment in ...